Spots Global Cancer Trial Database for A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Official Title: A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers
Study ID: NCT02452268
Conditions
Study Description
Brief Summary: Phase I/Ib multicenter clinical trial. Single agent dose escalation of NIZ985 followed by expansion. Second escalation of NIZ985 in combination with PDR001 followed by expansion
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Cancer Institute National Cancer Institute, Bethesda, Maryland, United States
Washington University School of Medicine SC, Saint Louis, Missouri, United States
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Providence Portland Medical Center SC, Portland, Oregon, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
University of Wisconsin, Madison, Wisconsin, United States
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
